Top 5 Japanese Stocks To Invest In 2014

Despite strong new models like the Impala sedan, a new survey found that GM's Chevrolet brand still trails most rivals in customer satisfaction. Photo credit: General Motors.

A new survey released last week showed that the top Japanese automakers lead General Motors (NYSE: GM  ) , Ford (NYSE: F  ) , and Chrysler in customer satisfaction -- and despite Detroit's recent quality gains, the gap may be widening.

What's going on, and is this something that could derail GM's turnaround? In this video, Fool contributor John Rosevear digs into the survey and offers his view on the real�reason GM still lags Toyota (NYSE: TM  ) and Honda (NYSE: HMC  ) in customer satisfaction.

GM still has some work to do, but Ford's turnaround has already rewarded shareholders. But for Ford's stock to really soar, a few more critical things need to fall into place. In The Motley Fool's special free report titled "5 Secrets to Ford's Future" we outline the key factors every Ford investor needs to watch. Just�click here�now for your free report.

5 Best Trucking Stocks To Watch Right Now: Greenhunter Resources Inc (GRH)

GreenHunter Resources, Inc., formerly GreenHunter Energy, Inc., incorporated on June 7, 2005, is engaged in providing Total Water Management Solutions to oil and gas operators who are active in the Marcellus, Eagle Ford and Bakken shale plays. The Company operates in three segments: Wind Energy, Water Management and Biomass. All of the Company�� segments are in development stages with no operations. The Company assembled a suite of water management products and services and markets them under the Total Water Management Solutions brand. The Company�� operations includes Total Water Management Solutions, Frac-Cycle, remote access management compliance asset tracking (RAMCAT), equipment and tank rentals, disposal wells, MAG Tank and salt water disposal animation. On February 17, 2012, the Company closed on the acquisition of 100% of the ownership interest of three fully operational commercial salt water disposal (SWD) wells and associated facilities located in Washington County, Ohio and Lee County, Kentucky. In March 2013, GreenHunter Water, LLC closed the purchase of a 10.8 acre barging terminal facility located in Wheeling, Ohio County, West Virginia. In February 2014, its wholly owned subsidiary, GreenHunter Water, LLC, sold its Kenedy Hunter salt water disposal (SWD) facilities and a SWD permit and surface acreage located at another South Texas property to Sable Environmental, LLC.

The Company�� subsidiary GreenHunter Water, LLC (GreenHunter Water) is focused on water resource management specifically as it pertains to the unconventional oil and natural gas shale resource plays with its business operations in the Appalachian and South Texas basins. GreenHunter Water engaged in providing a full range of solutions to address producers��needs and is built upon an identified need in the oilfield, to deliver a Total Water Management Solution to its customer base through long term agreements. The Company�� Total Water Management Solutions are custom developed to meet producers��wat! er resource planning needs. These solutions include owning and operating saltwater disposal facilities, fluids handling and hauling and logistics services, frac tank and next-generation modular above-ground tank rentals, mobile water treatment technologies and remote asset tracking to provide as value added services to its customers.

The Company�� asset included a fleet of nine water hauling vacuum trucks, and 37 frac tanks (500 barrel capacity each). As of December 31, 2011, total salt water disposal capacity is 9,000 barrels per day, of which 6,000 barrels per day is from two wells located in Ohio and approximately 3,000 barrels per day is from one well located in Kentucky. The Company is engaged in exploring various alternative means of water transport that include temporary and permanent above-ground or below-ground pipeline systems, and the use of rail and barge transport.

GreenHunter Water has assembled a variety of equipment and tanks for rental. Products available in the Eagle Ford and Marcellus Shale areas include 500 barrel frac Tanks, 425 barrel Weir Tanks, modular above-ground temporary storage tanks to replace frac ponds, available up to 41,000 barrel in capacity, frac manifolds and glass lined steel tanks, up to 100,000 barrel. During the year ended December 31, 2011, the Company Completed a project, that included the removal of chemicals and impurities in a sufficient amount for reuse in new wells that were scheduled for fracture stimulation. The project also included the treatment of a gel frac flowback and multiple sources of flowback water blended together. The Company purchased equipment assets to be used to service a long term contract to haul and dispose produced water for several oil companies that control mineral leasehold acreage positions in the Marcellus and Utica Shale plays located in Pennsylvania, West Virginia and Ohio. The equipment consists of five Peterbilt 388 trucks, five 130 barrel Vacuum Trailers and five vacuum pumps and related equipme! nt.

The Company�� water treatment services name is Frac-Cycle. Frac-Cycle�� flexible design allows the user to take in flow-back or produced water and recycle to either clean brine or fresh water. Recycled water can be used in subsequent frac jobs and in some cases an NPDES permit can be obtained to discharge fresh water into a stream. The Company�� RAMCAT is a system and compliance tool that bundles a combination of its software, advanced hardware and communications technologies to provide a method for remote activity observation via a Web-based portal for management of well-head fluids. RAMCAT includes online data monitoring, which provides oil and natural gas producers near real-time dynamic information on fluid levels, tank temperature, recent transactions, date and time of on-load and off-load, truck and driver identification, H2S and critical condition alarms and battery voltage.

Advisors' Opinion:

• [By James E. Brumley]

  In a perfect world, a stock's price is merely a reflection of a predictable combination of a company's history and forward-looking prospects. We don't live - or trade - in a perfect world though. In the real world, a chart not only tells a story, but illustrates traders' changing opinion of a stock. The good news is, traders move, thing, buy, and sell in fairly predictable patterns, and when you see certain hints fall in place, you can make a very good trade. Enter Authentidate Holding Corp. (NASDAQ:ADAT) and Greenhunter Resources Inc. (NYSEMKT:GRH). Both GRH as well as ADAT have taken on a bullish shape as of today, and both are apt to be at much higher levels in the foreseeable future.

Top 5 Japanese Stocks To Invest In 2014: BioTime Inc (BTX)

BioTime, Inc., incorporated on November 30, 1990, is a biotechnology company focused on the emerging field of regenerative medicine. Its commercial strategy is focused on its line of research products, such as ACTCellerate cell lines and associated ESpan culture media, HyStem hydrogels, human embryonic stem (hES) cell lines, and royalties from Hextend. Its focus is to provide regenerative therapies for age-related degenerative diseases. In January 2011, the Company acquired the assets of Cell Targeting, Inc. (CTI), a biotechnology company focused on methods of painting molecules on the surface of cells, which in turn causes the cells to adhere to particular tissues, such as those afflicted with disease. On March 21, 2011, the Company acquired Glycosan BioSystems, Inc. (Glycosan) through a merger of Glycosan with OrthoCyte Corporation (OrthoCyte). Through the merger, OrthoCyte acquired all of Glycosan�� assets, including Glycosan�� Hystem hydrogel product line. In March 2011, the Company entered into an agreement with XenneX, Inc., pursuant to which it organized LifeMap Sciences, Inc. (LifeMap), a subsidiary formed to advance the development and commercialization of its human embryonic stem (hES) cell data base. In August 2011, four hES cell lines (ESI-035, ESI-049, ESI-051 and ESI-053) developed by its subsidiary ES Cell International (ESI) were approved by the National Institutes of Health (NIH) for inclusion in the NIH Human Embryonic Stem Cell Registry. In May 2012, the Company acquired XenneX, Inc., through a merger of XenneX into LifeMap Sciences. In September 2012, the Company formed a wholly owned subsidiary, BioTime Acquisition Corporation. In October 2013, Geron Corporation announced the closing of the transaction to divest the Company's stem cell assets to Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc.

HyStem is a biomaterial, which mimics the human extracellular matrix, which is the network of molecules surrounding cells in organs and tissues which is essent! ial to cellular function. Its HyStem hydrogels may have other applications when combined with the diverse and scalable cell types its scientists have isolated from hES cells. HyStem-Rx is a clinical grade formulation of HyStem-C, a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. Its subsidiary, OncoCyte Corporation, is developing PanC-Dx, a non-invasive blood-based cancer screening test designed to detect the presence of various human cancers, including cancers of the breast, lung, bladder, uterus, stomach, and colon, during routine check -ups. BioTime Asia, Limited (BioTime Asia) sells products for research use and may develop therapies to treat cancer and neurological and orthopedic diseases in Asia. OrthoCyte Corporation (OrthoCyte) is developing therapies to treat orthopedic disorders, diseases and injuries. ReCyte Therapeutics, Inc. (ReCyte Therapeutics) is developing therapies for age-related cardiovascular and blood disorders. Cell Cure Neurosciences Ltd. (Cell Cure Neurosciences), is a biotechnology company focused on developing stem cell-based therapies for retinal and other neurological disorders, including the development of retinal pigment epithelial (RPE) cells for the treatment of age-related macular degeneration. LifeMap Sciences, Inc. (LifeMap) is advancing the development and commercialization of our embryonic stem cell database and plans to make the database available for the marketing of research products and for use by stem cell researchers at pharmaceutical and biotechnology companies and other institutions via paid subscriptions or on a fee per use basis.

The Company�� blood plasma expander product, Hextend, is a physiologically balanced intravenous solution used in the treatment of hypovolemia, a condition caused by low blood volume, often from blood loss during surgery or injury. Hextend maintains circulatory system fluid volume and blood pressure, and keeps vital organs perfused during surgery and t! rauma car! e. Hextend is manufactured and distributed in the United States by Hospira, Inc., and in South Korea by CJ CheilJedang (CJ), under license from it.

Human Embryonic Stem Cell Lines for Research Use

Combined with the Company�� ACTCellerate technology, it derives of a range of markets human embryonic progenitor cells (hEPCs). ESI�� six current good manufacturing practices (cGMP) hES cell lines have been approved by the NIH for inclusion in the Human Embryonic Stem Cell Registry, which renders those cell lines eligible for use in federally funded research. The ESI hES cell lines are available for purchase through www.biotimeinc.com. It also markets hEPCs developed using ACTCellerate technology. Its hEPCs are also available for sale through www.biotimeinc.com. It derived the complete genome sequence of five of the ESI hES cell lines to facilitate the development of products derived from these cell lines. It has made these GMP-grade cell lines, along with certain documentation and complete genomic deoxyribonucleic acid (DNA) sequence information, available for sale.

The Company offers human stem cell products and technology that can be used by researchers at universities and at companies in the bioscience and biopharmaceutical industries. It has developed research and clinical grade hES cell lines, which it markets for both basic research and therapeutic product development. It also markets human embryonic progenitor cell (hEPCs) developed using ACTCellerate technology. These hEPCs are purified lineages of cells, which are intermediate in the developmental process between embryonic stem cells and fully differentiated cells. The ACTCellerate cell lines are also available for purchase through http://www.biotimeinc.com.

Human Embryonic Progenitor Cells

Through the Company�� subsidiary ReCyte Therapeutics, it had a license from Advanced Cell Technology, Inc. (ACT) to use ACTCellerate technology, and the rights to market more than 200 human c! ell types! made using that process. ACTCellerate allows the rapid isolation of hEPCs, which are cells that are intermediate in the developmental process between embryonic stem cells and fully differentiated cells.

Through an agreement with ReCyte Therapeutics, Millipore Corporation became a global distributor of ACTCellerate hEPC lines. In addition to the products, which it is co-marketing with Millipore, it offers 92 other ACTCellerate hEPC lines for purchase at www.biotimeinc.com. Through its subsidiary LifeMap, it provides online biomedical database services to increase awareness of molecular markers and diverse cell types comprising its ACTCellerate hEPC lines. It also focuses to market additional cell types manufactured with its PureStem technology. PureStem cell lines are produced by the exogenous expression of specific transcription factors, which regulate the differentiation of cell types from hES or induced pluripotent stem (iPS) cells. BioTime Asia has an agreement with Shanghai Genext Medical Technology Co., Ltd. to sell ACTCellerate hEPC lines and related ESpan growth media to the medical and biological research communities in China, Taiwan, Hong Kong, and Macau on an exclusive basis. The marketing agreement includes provisions for an initial stocking inventory and annual milestones to maintain exclusivity. The Company�� California Institute of Regenerative Medicine (CIRM)-funded research addresses the need for industrial scale production of purified therapeutic cells.

hES Cells Carrying Genetic Diseases

The Company focuses to add to its product line muscle progenitor cells produced from five hES cell lines carrying genes for Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, spinal muscular atrophy Type I, facioscapulohumeral muscular dystrophy 1A, and Becker muscular dystrophy. It obtained the diseased hES cell lines from Reproductive Genetics Institute (RGI).

ESpan Cell Growth Media

The Company is marketing a range of! cell-gro! wth media products called ESpan. These growth media are optimized for the growth of hEPC types. Cells need to be propagated in liquid media, in both the laboratory setting, where basic research on stem cells is performed, and in the commercial sector. Its ESpan products are marketed through Millipore and Genext.

ESpy Cell Lines

The Company focuses for development of ESpy cell lines. The ability of the ESpy cells to emit light will allow researchers to track the location and distribution of the cells in both in vitro and in vivo studies.

HyStem Hydrogel for Research and HyStem-Rx for Cell Delivery Medical Devices

HyStem is a patented biomaterial that mimics the ECM, the network of molecules surrounding cells in organs and tissues that is essential to cellular function. Its HyStem technology forms the foundation for stem cell delivery products in both the adult and embryonic stem cell marketplace, including products manufactured using its ACTCellerate technology. As an injectable product, HyStem-Rx may address need in cosmetic and reconstructive surgeries and other procedures by transplanting adipose derived cells or other adult stem cells. The transfer of cells in HyStem-Rx localizes the transplanted cells at the intended site and by providing a three-dimensional scaffold upon which cells can rebuild normal tissue. HyStem-Rx may support other emerging cell and tissue transplant therapies, such as those derived from hES and iPS cells, in addition to its potential application in the treatment of a range of conditions such as osteoarthritis, brain tumors, stroke, bone fracture, and wounds.

Advisors' Opinion:

• [By Brian Pacampara]

  Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company BioTime (NYSEMKT: BTX  ) has received the dreaded one-star ranking.

• [By John Udovich]

  Stem cell stocks have not exactly been the best performers lately in part because the controversy over their use has died down over the years while major breakthroughs have been few or far between, but the industry along with small cap stem cell stocks Pluristem Therapeutics Inc (NASDAQ: PSTI), BioTime, Inc (NYSEMKT: BTX) and BioRestorative Therapies (OTCBB: BRTX) are still quietly producing their share of news or minor breakthroughs worth taking note of. Just consider the following stem cell news or news from small cap players in the sector:

Top 5 Japanese Stocks To Invest In 2014: Agility Public Warehousing Co KSC (AGLTY)

Agility Public Warehousing Company KSC is a Kuwait-based company engaged, along with its subsidiaries, in the provision of global integrated logistics solutions. The Company is organized into two business segments: the Logistic and Related services segment provides logistics offering to its clients, including freight forwarding, transportation, contract logistics, project logistics and fairs and events logistics, and the Infrastructure segment provides other services, which include industrial real estate airport and airplane ground handling and cleaning services, customs consulting, private equity and waste recycling. The Company operates under the brand name of Agility. The Company�� subsidiaries include Global Express Transport Co. WLL, PWC Transport Company WLL, Agility DGS Logistics Services KSCC and Gulf Catering Company for General, among others. Advisors' Opinion:

• [By Fiona MacDonald]

  The Kuwait SE Price Index rose for a sixth day, climbing 0.5 percent to 6,851.17 at the close. Kuwait Real Estate Co. (KRE) climbed to the highest level in a month. Agility (AGLTY) advanced 1.7 percent after winning a $190 million UN contract in Sudan�� Darfur region. The Bloomberg GCC 200 Index, which tracks the biggest 200 companies in the Gulf Cooperation Council, fell 0.1 percent.

Top 5 Japanese Stocks To Invest In 2014: Apollo Investment Corporation(AINV)

Apollo Investment Corporation is business development company and operates as a closed-end management investment company. The company invests in middle market companies. It provides direct equity capital, mezzanine and senior secured loans, and subordinated debt and loans. It also seeks to invest in PIPES transactions. The company may also invest in public companies that are thinly traded and may acquire investments in the secondary market. It prefers to invest in warrants, makes equity co-investments, and may also invest in cash equivalents, U.S. government securities, high-quality debt investments that mature in one year or less, high-yield bonds, distressed debt, non-U.S. investments, or securities of public companies that are not thinly traded. The company typically invests in building materials, business services, cable television, chemicals, consumer products, direct marketing, distribution, energy and utilities, financial services, healthcare, manufacturing, media, publishing, retail and transportation. It primarily invests between $20 million and $250 million in its portfolio companies. The company seeks to make investments with stated maturities of five to ten years.

Advisors' Opinion:

• [By MONEYMORNING]

  He's much better off in "total return" holdings, like Apollo Investment Corp. (Nasdaq: AINV) which we covered right here, and Kinder Morgan Energy Partners LP (NYSE: KMP), another long-term winner.

• [By James Brumley]

  The seller will let up as soon as the news is a fading memory, which should be soon.

  Apollo Investment Corp. (AINV)

  AINV Dividend Yield: 9.7%

• [By Rich Bieglmeier]

  Expensive or not, dividend investors might be interested in this week's highlighted insider buying candidate: Apollo Investment Corporation (AINV).

• [By Tim Melvin]

  Here are a couple private equity-powered dividend stocks on my radar right now:

  Apollo Investment (AINV)

  Apollo Global Management (APO) is one of the world�� largest asset management and private equity firms with more than $100 billion under management. Its largest publicly offered vehicle is Apollo Investment (AINV), a business development company that invests in and ends to middle-market companies and pays out 90% of its net income to shareholders.